Table 1.
Baseline characteristics of 272 patients who received combination IFN-α and RBV therapy for HCV
| Demographics | |
| Mean age (years) | 42 ± 8 |
| Males | 150 (55%) |
| Caucasians | 204 (75%) |
| Asians | 22 (8%) |
| Weight (kg) | 79 ± 18 |
| HCV Genotype | |
| 1 | 136 (50%) |
| 2 | 22 (8%) |
| 3 | 103 (38%) |
| 4 | 11 (4%) |
| Liver Function Tests (RR) | |
| Albumin (36–48 g/L) | 41 ± 2 |
| Serum Bilirubin (2–20 μmol/L) | 15 ± 6 |
| Alanine Aminotransferase (< 45 U/L) | 133 ± 58 |
| γ-Glutamyl Transpeptidase (1–30 U/L) | 98 ± 46 |
| Prothrombin time (11–18 seconds) | 15 ± 3 |
| Haematological Parameters (RR) | |
| Haemoglobin (115–165 g/L) | 142 ± 16 |
| White cell counts (4.0–11.0 × 106/mL) | 7.1 ± 2.0 |
| Platelets (150–400 × 109/mL) | 168 ± 49 |